Serum osteoglycin is stable during various glycemic challenges in healthy men

TY - JOUR

T1 - Serum osteoglycin is stable during various glycemic challenges in healthy men

AU - Starup-Linde, Jakob

AU - Westberg-Rasmussen, Sidse

AU - Viggers, Rikke

AU - Al-Mashhadi, Zheer Kejlberg

AU - Handberg, Aase

AU - Vestergaard, Peter

AU - Gregersen, Søren

N1 - Publisher Copyright: © The Author(s) 2024.

PY - 2024/9

Y1 - 2024/9

N2 - Purpose: Osteoglycin is hypothesized to be metabolically active and may enhance insulin action. We hypothesized that osteoglycin levels increase during hyperglycemia as a physiological response to enhance the effects of insulin. Methods: Eight healthy males were included in a cross-over study consisting of three study days following an 8 h fast. First, we performed an oral glucose tolerance test (OGTT); second, an isoglycemic intravenous glucose infusion (IIGI); and third, a control period consisting of a three hour fast. We analyzed blood samples for circulating osteoglycin levels during the study days. Repeated measures ANOVA was performed to compare levels of s-osteoglycin between OGTT, IIGI, and the fasting control. Results: There were no differences in baseline osteoglycin levels among study days (p > 0.05). We observed no significant changes neither in absolute s-osteoglycin levels by time (p = 0.14) nor over time by study day (p = 0.99). Likewise, we observed no significant changes in percentage s-osteoglycin levels neither by time (p = 0.11) nor over time by study day (p = 0.89). Conclusion: We found that s-osteoglycin levels were stable for three hours during OGTT, IIGI, and fasting in healthy males. Based on the present study, circulating s-osteoglycin levels may be measured independently of fasting or non-fasting conditions. Furthermore, circulating physiological levels of glucose and insulin did not affect s-osteoglycin levels.

AB - Purpose: Osteoglycin is hypothesized to be metabolically active and may enhance insulin action. We hypothesized that osteoglycin levels increase during hyperglycemia as a physiological response to enhance the effects of insulin. Methods: Eight healthy males were included in a cross-over study consisting of three study days following an 8 h fast. First, we performed an oral glucose tolerance test (OGTT); second, an isoglycemic intravenous glucose infusion (IIGI); and third, a control period consisting of a three hour fast. We analyzed blood samples for circulating osteoglycin levels during the study days. Repeated measures ANOVA was performed to compare levels of s-osteoglycin between OGTT, IIGI, and the fasting control. Results: There were no differences in baseline osteoglycin levels among study days (p > 0.05). We observed no significant changes neither in absolute s-osteoglycin levels by time (p = 0.14) nor over time by study day (p = 0.99). Likewise, we observed no significant changes in percentage s-osteoglycin levels neither by time (p = 0.11) nor over time by study day (p = 0.89). Conclusion: We found that s-osteoglycin levels were stable for three hours during OGTT, IIGI, and fasting in healthy males. Based on the present study, circulating s-osteoglycin levels may be measured independently of fasting or non-fasting conditions. Furthermore, circulating physiological levels of glucose and insulin did not affect s-osteoglycin levels.

KW - Glucose

KW - Insulin

KW - Isoglycemic intravenous glucose infusion

KW - Oral glucose tolerance test

KW - Osteoglycin

UR - http://www.scopus.com/inward/record.url?scp=85188955762&partnerID=8YFLogxK

U2 - 10.1007/s12020-024-03789-1

DO - 10.1007/s12020-024-03789-1

M3 - Journal article

C2 - 38549032

AN - SCOPUS:85188955762

SN - 1355-008X

VL - 85

SP - 1117

EP - 1121

JO - Endocrine

JF - Endocrine

IS - 3

ER -